Canaccord Genuity Starts Pacira Pharmaceuticals (PCRX) at Buy
Tweet
Share
E-mailGet Alerts PCRX Hot Sheet
Price: $25.02 -2.19%
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Rating Summary:
11 Buy, 16 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 33 | Down: 45 | New: 4
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Pacira Pharmaceuticals (NASDAQ: PCRX) with a Buy rating and a price target of $109.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $88.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Pacira Pharmaceuticals (PCRX) PT Raised to $25 at RBC Capital
- Bernstein SocGen Group Starts Csquare Inc (CSQR) at Outperform
- Pacira BioSciences Announces Publication of Positive Two-Year Phase 1 Data For PCRX-201 in Annals of the Rheumatic Diseases
Create E-mail Alert Related Categories
New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
